In a welcome move, Haleon ADR saw its Relative Strength Rating rise from 70 to 79 on Monday.
IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners often have an RS Rating north of 80 as they launch their largest runs. See if Haleon ADR can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
Haleon ADR is working on a cup without handle with a 10.80 buy point. See if the stock can clear the breakout price in volume at least 40% above average.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 17%, compared to 0% in the prior report. Revenue increased from 0% to 9%. The next quarterly results are expected on or around Feb. 27.
The company holds the No. 1 rank among its peers in the Medical-Generic Drugs industry group. Collegium Pharmaceutical and Dr. Reddy's Labs ADR are also among the group's highest-rated stocks.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
